WallStSmart

Quest Diagnostics Incorporated (DGX)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 304% more annual revenue ($44.56B vs $11.04B). TMO leads profitability with a 15.0% profit margin vs 9.0%. DGX appears more attractively valued with a PEG of 1.55. TMO earns a higher WallStSmart Score of 62/100 (C+).

DGX

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 6.0Value: 8.7Quality: 5.3
Piotroski: 2/9Altman Z: 2.29

TMO

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 7.3Quality: 6.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DGXUndervalued (+2.6%)

Margin of Safety

+2.6%

Fair Value

$214.96

Current Price

$195.26

$19.70 discount

UndervaluedFair: $214.96Overvalued
TMOSignificantly Overvalued (-23.4%)

Margin of Safety

-23.4%

Fair Value

$384.60

Current Price

$474.39

$89.79 premium

UndervaluedFair: $384.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DGX1 strengths · Avg: 8.0/10
Price/BookValuation
3.0x8/10

Reasonable price relative to book value

TMO3 strengths · Avg: 8.3/10
Market CapQuality
$176.23B9/10

Large-cap with strong market position

Operating MarginProfitability
21.2%8/10

Strong operational efficiency at 21.2%

Free Cash FlowQuality
$2.99B8/10

Generating 3.0B in free cash flow

Areas to Watch

DGX2 concerns · Avg: 3.5/10
PEG RatioValuation
1.554/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.764/10

Expensive relative to growth rate

P/E RatioValuation
26.7x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : DGX

The strongest argument for DGX centers on Price/Book.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : DGX

The primary concerns for DGX are PEG Ratio, Piotroski F-Score.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

TMO carries more volatility with a beta of 0.97 — expect wider price swings.

TMO is growing revenue faster at 7.2% — sustainability is the question.

TMO generates stronger free cash flow (3.0B), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TMO scores higher overall (62/100 vs 61/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Quest Diagnostics Incorporated

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?